iA Global Asset Management Inc. Grows Stake in Teva Pharmaceutical Industries Ltd. $TEVA

iA Global Asset Management Inc. lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 9.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 208,709 shares of the company’s stock after purchasing an additional 18,100 shares during the quarter. iA Global Asset Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $4,216,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Cromwell Holdings LLC grew its position in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares in the last quarter. Advisors Asset Management Inc. bought a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at about $41,000. Sound Income Strategies LLC boosted its position in shares of Teva Pharmaceutical Industries by 3,715.8% during the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock valued at $49,000 after acquiring an additional 2,824 shares during the last quarter. JTC Employer Solutions Trustee Ltd purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $65,000. Finally, MAI Capital Management increased its position in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.5%

Shares of TEVA stock opened at $31.83 on Friday. The business has a 50-day moving average of $29.64 and a 200 day moving average of $22.58. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.42. The stock has a market capitalization of $36.51 billion, a PE ratio of 53.05, a P/E/G ratio of 1.81 and a beta of 0.66.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TEVA. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. Barclays began coverage on Teva Pharmaceutical Industries in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Buy” and an average price target of $33.67.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president directly owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 622,060 shares of company stock worth $17,076,965. 0.49% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.